Article Versions Notes

Awah CU, Mun JS, Paragodaarachchi A, Boylu B, Ochu C, Matsui H, Ogunwobi OO. The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer. Cancers. 2024; 16(15):2663. https://doi.org/10.3390/cancers16152663

Awah, Chidiebere U., Joo Sun Mun, Aloka Paragodaarachchi, Baris Boylu, Chika Ochu, Hiroshi Matsui, and Olorunseun O. Ogunwobi. 2024. "The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer" Cancers 16, no. 15: 2663. https://doi.org/10.3390/cancers16152663

Awah, C. U., Mun, J. S., Paragodaarachchi, A., Boylu, B., Ochu, C., Matsui, H., & Ogunwobi, O. O. (2024). The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer. Cancers, 16(15), 2663. https://doi.org/10.3390/cancers16152663